Research in the Nicholas Dalesio Lab is currently examining pre-surgical predictors of post-surgical respiratory complications in children with obstructive sleep apnea and sleep-disordered breathing; the impact of anesthesia and pharmacological agents on upper airway physiology; and techniques for pediatric airway imaging.

Our IndoUS team, based both in Baltimore and in India, specializes in international clinical research (cohort studies and clinical trials), public health implementation science and education in infectious diseases, HIV/AIDS, tuberculosis (TB), vaccine preventable illnesses, antimicrobial resistant infections, and more recently COVID. Since 2003, our work has been focused primarily on India, where we are engaged in several Indo-JHU and international research collaborations. We partner with several leading medical and research institutions in India (e.g. BJGMC, DY Patil, Hinduja Hospital, KEM, Bharati Vidyapeeth, NIRT, JIPMER, CMC, Medanta, IISER, YRG, IIT), as well as others in sub-Saharan Africa, US and Brazil. We are actively involved in the following consortia: 1) Indo-US Vaccine Action Program sponsored RePORT India TB research consortium, which is funded by the US National Institutes of Health (NIH) and the government of India, Department of Biotechnology. 2) RePORT International TB Research Consortium, a multilateral global consortia for TB research, 3) US NIH funded multi-country HIV and TB trials consortia of the AIDS Clinical Trials Group (ACTG) and the International Maternal Pediatric Adolescent AIDS Trials Network (IMPAACT) Network, 4) NIH and AmFAR funded IeDea HIV/TB Working Group and the Treat Asia-IeDEA HIV and TB epidemiology databases, and 5) CDC SHEPHERD AMR studies. Our group has been awarded research grants from the US NIH, US CDC, UNITAID, Indian government, and several philanthropic foundations to investigate infectious diseases of importance to India and beyond.

The Amita Gupta Lab focuses on drug trials to prevent and treat HIV, tuberculosis (TB) and other co-morbidities in adults, including pregnant women and children who reside in low-income settings. We also conduct cohort studies assessing HIV, inflammation and nutrition in international settings; TB in pregnancy; and risk factors for TB in India (CTRIUMPH). We collaborate with several faculty in the Center for TB Research, Division of Infectious Diseases and the School of Public Health.

The goal of the Johns Hopkins Brain Cancer Biology and Therapy Laboratory is to locate the genetic and genomic changes that lead to brain cancer. These molecular changes are evaluated for their potential as therapeutic targets and are often mutated genes, or genes that are over-expressed during the development of a brain cancer. The brain cancers that the Riggins Laboratory studies are medulloblastomas and glioblastomas. Medulloblastomas are the most common malignant brain tumor for children and glioblastomas are the most common malignant brain tumor for adults. Both tumors are difficult to treat, and new therapies are urgently needed for these cancers. Our laboratory uses large-scale genomic approaches to locate and analyze the genes that are mutated during brain cancer development. The technologies we now employ are capable of searching nearly all of a cancer genome for molecular alterations that can lead to cancer. The new molecular targets for cancer therapy are first located by large scale gene expression analysis, whole-genome scans for altered gene copy number and high throughput sequence analysis of cancer genomes. The alterations we find are then studied in-depth to determine how they contribute to the development of cancer, whether it is promoting tumor growth, enhancing the ability for the cancer to invade into normal tissue, or preventing the various fail-safe mechanisms programmed into our cells.

Researchers in the Elizabeth Hunt Lab study innovative ways to improve the care quality and clinical outcomes of children who suffer cardiopulmonary arrest. Our work includes implementing rapid-response systems, capturing and analyzing cardiac-arrest data, and redesigning medical devices and simulators. We've introduced novel simulation approaches to education, including data-driven debriefing and the Rapid Cycle Deliberate Practice approach.

Research in the Eric McCollum Lab focuses on pediatric pulmonary medicine, particularly pulmonary diseases among children in undeveloped, low-resource countries. We are taking part in the IMPACT trial, which looks at the impact of bubble continuous positive airway pressure (bCPAP) on the mortality of Malawian children with pneumonia.

Research in the Wendy Bennett Lab focuses on weight management and women's health. We also examine health disparities in low-income children and pregnant and postpartum women.

Research in the Lilly Engineer Lab examines the quality and safety of medical care, with a focus on rural and underserved communities. Our current research evaluates methods for improving immunization rates among inner-city populations of school-aged children. We are also exploring the effect of federal policy changes and health care market forces on rural hospitals in the United States.

Research in the M-Irfan Suleman Lab focuses on better understanding and controlling pediatric pain. We've played a key role in the discovery of novel techniques for post-surgical pain management in children.

The Michelle Eakin Lab conducts research on behavioral science and adherence and asthma outcomes in inner-city children. Our studies into behavioral science have included exploring the impact of medication adherence on lung health outcomes in patients with cystic fibrosis, disparities in anti-hypertensive medication adherence in adolescents and other key topics. We also investigate methods for improving asthma care and treatment as well as health disparities among various ethnicities, particularly in pediatric patients.